Trial Profile
Two-dose, Positive Drug Control, Multicentre, Randomized, Double-blind Study of Recombinant Human Parathyroid Hormone for Injection(rhPTH)(1-34) Once a Week to Treat Postmenopausal Osteoporosis Women for the Evaluation the Pharmacokinetics and Safety and to Explore Therapeutic Effects
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Teriparatide (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Shenzhen Salubris Pharmaceuticals
- 02 Nov 2018 New trial record